PCSK9 vaccines: a promising new strategy for the treatment of hypercholesterolemia?

J Lipid Res. 2024 Mar;65(3):100524. doi: 10.1016/j.jlr.2024.100524. Epub 2024 Feb 17.

Authors

Bryce Chackerian¹, Alan T Remaley²

Affiliations

¹ Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA. Electronic address: BChackerian@salud.unm.edu.
² Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural

MeSH terms

Anticholesteremic Agents*
Cholesterol, LDL
Humans
Hypercholesterolemia* / therapy
Hyperlipidemias*
Proprotein Convertase 9 / genetics
Vaccines*

Substances

PCSK9 protein, human
Proprotein Convertase 9
Cholesterol, LDL
Anticholesteremic Agents
Vaccines

Grants and funding

R01 HL131696/HL/NHLBI NIH HHS/United States